Get in touch with RARE Concierge.

Contact RARE Concierge

Synonyms: CDG syndrome type Iq | CDG-Iq | CDG1Q | Congenital disorder of glycosylation type 1q | Congenital disorder of glycosylation type Iq

SRD5A3-CDG is a rare non X-linked congenital disorder of glycosylation due to steroid 5 alpha reductase type 3 deficiency characterized by a highly variable phenotype typically presenting with severe visual impairment variable ocular anomalies (such as optic nerve hypoplasia/atrophy iris and optic nerve coloboma congenital cataract glaucoma) intellectual disability cerebellar abnormalities nystagmus hypotonia ataxia and/or ichthyosiform skin lesions. Other reported manifestations include retinitis pigmentosa kyphosis congenital heart defects hypertrichosis and abnormal coagulation.

Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview. Reference: Access aggregated data from Orphanet at Orphadata. Orphadata: Free access data from Orphanet. © INSERM 1999. Available on Data version June 2024

Newly diagnosed with

Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.

Get Concierge Help

Advocacy Organizations


Our mission is to promote greater awareness and understanding of CDG & NGLY1-Deficiency, to provide information and support to families affected by CDG & NGLY1, and to advocate for and fund scientific research to advance the diagnosis and treatment of CDG & NGLY1-Deficiency.

Mississippi Metabolics Foundation

Our mission at Mississippi Metabolics Foundation (MMF) is to advocate, educate, and support families in MS affected by genetic metabolic disorders/inborn errors of metabolism (IEM's). MMF promotes initiatives and further advancements in legislation, education, research, clinical trials, studies, therapies, targeted treatments, and eventual cures for IEM’s and all rare diseases.

Don't see your organization here. Let us know here.

Clinical Trials

For a list of clinical trials in this disease area, please click here.